Appoints new Chief Executive and Chief Operating Officer
The Aenova Group has expanded its management team by appointing Mohammad Naraghi, to the position of Chief Executive Officer. He succeeds Dr Axel Müller, who had acted as interim CEO since 2015. Dr Naraghi has many years’ international experience in the healthcare and life sciences industry. He will be responsible for strategy, marketing and distribution as well as R&D, communications, quality and human resources.
In addition, Marco Robert Gorgas has joined the German firm as Chief Operating Officer. He has many years’ pharmaceutical experience and was previously Senior Vice President Global Operations at Stada Arzneimittel. From 1 June 2016, he will be in charge of production and supply chain management at Aenova.
Dr Markus Böning has been Chief Financial Officer of the Aenova Group since August 2015. His responsibilities include finance, controlling, investor relations, IT and procurement.
'With these three managerial personalities, the management team of the Aenova Group is extremely well positioned. We’re convinced that the management team will further intensify the Group's integration, control its operations with excellence and further reinforce Aenova’s position as a leading partner to the pharmaceuticals industry,' said Stefan Zuschke, Managing Partner at BC Partners and a member of the Supervisory Board.
The key objectives of the Aenova Group in the coming years will be to make further production quality improvements, optimise the production structure and foster sustainable growth in Europe and worldwide.
Dr Naraghi has spent nearly his entire professional life in various international managerial positions in the healthcare and life sciences industry: from 2013 to 2015, he was CEO Germany of the Synlab Group, a leading provider of laboratory services in Europe. Before this he was at the New York Head Office of IBM and responsible as Global Leader Healthcare and Life Sciences for the global service business with pharmaceuticals, medtech/biotech and healthcare customers.
Earlier in his professional career he worked for Dutch pharmaceuticals wholesaler and retailer Mediq, where he was responsible on the Management Board for parts of the European as well as US business. Previously, at Siemens Healthcare, he was the first CEO of the global diagnostics section, Siemens Diagnostics, which he built up following the acquisition of Diagnostic Products Corporation (LA) as well as the diagnostics business of Bayer Healthcare (NY). Previously, as a member of the Global Executive Committee at Siemens Healthcare, he was in charge of Global Business Development.
From November 2009, Gorgas held various managerial positions with Stada Arzneimittel. From 2009 to 2010, he was responsible for the firm's Russian activities. From 2010 to 2014, as Vice President he was in charge of Stada's production sites. Most recently, as Senior Vice President Global Operations not only was he responsible for all Stada production sites but also for the firm’s international product transfers. Before that he spent more than 10 years with the business consultancy firm Capgemini in Germany, predominantly engaged in the life science division.